Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Io­n­is Phar­ma­ceu­ti­cals has inked a deal with Ot­su­ka, giv­ing the Japan­ese phar­ma Eu­ro­pean com­mer­cial rights to its Phase III pro­phy­lac­tic drug can­di­date for hered­i­tary an­gioede­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER